Dr Reddy's gets nod for amalgamation of Dr Reddy's Holdings into company

Shares of Dr Reddy's Laboratories on Friday settled at Rs 2,888.90 on the BSE, up 0.87 per cent from its previous close.

Drug major Dr Reddy's Laboratories on Friday said it has received shareholders nod for proposed amalgamation of Dr Reddy's Holdings Ltd into the company.

The resolution for the scheme was approved by 99.98 per cent votes of the total 13.10 crore votes casted by equity shareholders of the company, it said in a regulatory filing.

21,026 votes, which accounted for the rest 0.02 per cent, were posted against the resolution, it added.

The voting was conducted as per the directions of the Hyderabad Bench of the National Company Law Tribunal on November 22, 2019.

The meeting of equity shareholders was convened on January 2, 2020.

The board of Dr Reddy's Laboratories had on July 29, 2019, approved the amalgamation of Dr Reddy's Holdings Ltd, an entity held by the promoter group which holds 24.88 per cent equity shares of Dr Reddy's Laboratories, into the company.

The scheme would lead to simplification of the shareholding structure and reduction of shareholding tiers, the company had said.

"The Promoter Group cumulatively will continue to hold the same number of shares in the Company, pre and post the amalgamation," it had said.

Shares of Dr Reddy's Laboratories on Friday settled at Rs 2,888.90 on the BSE, up 0.87 per cent from its previous close.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel